Clinical Trial Update: Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or III Colon Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating toripalimab as adjuvant therapy after surgery in mismatch repair-deficient stage IIB/IIC/III colon cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colon Cancer

Drugs mentioned

• Toripalimab (Toripalimab)

Snippet

Sponsor: Emory University | Conditions: Localized Colon Carcinoma, Stage IIB Colon Cancer AJCC v8 | Phase 2 | Status: RECRUITING